- Home
- COEP vs FEMY Comparison
COEP vs FEMY Comparison
Compare COEP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- FEMY
- Stock Information
- Founded
- COEP 2017
- FEMY 2004
- Country
- COEP United States
- FEMY United States
- Employees
- COEP N/A
- FEMY N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- FEMY Medical/Dental Instruments
- Sector
- COEP Health Care
- FEMY Health Care
- Exchange
- COEP Nasdaq
- FEMY Nasdaq
- Market Cap
- COEP 32.0M
- FEMY 28.3M
- IPO Year
- COEP N/A
- FEMY 2021
- Fundamental
- Price
- COEP $8.95
- FEMY $0.80
- Analyst Decision
- COEP
- FEMY Strong Buy
- Analyst Count
- COEP 0
- FEMY 3
- Target Price
- COEP N/A
- FEMY $8.67
- AVG Volume (30 Days)
- COEP 28.9K
- FEMY 342.7K
- Earning Date
- COEP 05-14-2025
- FEMY 05-08-2025
- Dividend Yield
- COEP N/A
- FEMY N/A
- EPS Growth
- COEP N/A
- FEMY N/A
- EPS
- COEP N/A
- FEMY N/A
- Revenue
- COEP $62,874.00
- FEMY $1,699,232.00
- Revenue This Year
- COEP N/A
- FEMY $526.11
- Revenue Next Year
- COEP N/A
- FEMY $83.00
- P/E Ratio
- COEP N/A
- FEMY N/A
- Revenue Growth
- COEP N/A
- FEMY 61.97
- 52 Week Low
- COEP $2.31
- FEMY $0.69
- 52 Week High
- COEP $13.70
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- COEP 45.20
- FEMY 25.45
- Support Level
- COEP $9.14
- FEMY $0.69
- Resistance Level
- COEP $9.82
- FEMY $0.83
- Average True Range (ATR)
- COEP 0.54
- FEMY 0.06
- MACD
- COEP -0.06
- FEMY -0.02
- Stochastic Oscillator
- COEP 21.51
- FEMY 26.95
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.